BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37270586)

  • 1. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
    Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
    Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
    Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
    Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
    Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation.
    Backman S; Botling J; Nord H; Ghosal S; Stålberg P; Juhlin CC; Almlöf J; Sundin A; Zhang L; Moens L; Eriksson B; Welin S; Hellman P; Skogseid B; Pacak K; Mollazadegan K; Åkerström T; Crona J
    medRxiv; 2024 Jan; ():. PubMed ID: 38313278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
    Navale P; Chatterjee D; Itani M; Trikalinos NA
    Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of DNA methylation in human pancreatic neuroendocrine tumours.
    English KA; Thakker RV; Lines KE
    Endocr Oncol; 2023 Jan; 3(1):e230003. PubMed ID: 37434653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
    Ooki A; Osumi H; Fukuda K; Yamaguchi K
    Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Human Mammary Tumor Virus (HMTV) on the Expression of Epidermal Growth Factor Receptor (EGFR) and Death-Domain Associated Protein (DAXX) in Breast Carcinoma Tissues.
    Ali Naeem H; Nazar Ibraheim W; Abdullah Alomar SA
    Arch Razi Inst; 2023 Apr; 78(2):689-699. PubMed ID: 37396746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms.
    Bourdeleau P; Couvelard A; Ronot M; Lebtahi R; Hentic O; Ruszniewski P; Cros J; de Mestier L
    Ther Adv Med Oncol; 2023; 15():17588359231179310. PubMed ID: 37323185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
    Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
    Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
    Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
    NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.